Janus Kinase inhibitors (Jak inhibitors) are new drugs targeting the JAK/STAT pathways and are used in several diseases such as rheumatoid arthritis, inflammatory bowel disease, graft vs. host disease, and hemophagocytic lymphohistiocytosis (61). Here, SOAT1 is linked to hemophagocytic syndrome.